Skip to main content

Advertisement

Log in

Spontaneous T-cell responses against peptides derived from the Taxol resistance–associated gene-3 (TRAG-3) protein in cancer patients

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Expression of the cancer-testis antigen Taxol resistance–associated gene-3 (TRAG-3) protein is associated with acquired paclitaxel (Taxol) resistance, and is expressed in various cancer types; e.g., breast cancer, leukemia, and melanoma. Thus, TRAG-3 represents an attractive target for immunotherapy of cancer. To identify HLA-A*02.01–restricted epitopes from TRAG-3, we screened cancer patients for spontaneous cytotoxic T-cell responses against TRAG-3–derived peptides. The TRAG-3 protein sequence was screened for 9mer and 10mer peptides possessing HLA-A*02.01–binding motifs. Of 12 potential binders, 9 peptides were indeed capable of binding to the HLA-A*02.01 molecule, with binding affinities ranging from strong to weak binders. Subsequently, lymphocytes from cancer patients (9 breast cancer patients, 12 melanoma patients, and 13 patients with hematopoietic malignancies) were analyzed for spontaneous reactivity against the panel of peptides by ELISpot assay. Spontaneous immune responses were detected against 8 epitope candidates in 7 of 9 breast cancer patients, 7 of 12 melanoma patients, and 5 of 13 patients with hematopoietic malignancies. In several cases, TRAG-3–specific CTL responses were scattered over several epitopes. Hence, no immunodominance of any single peptide was observed. Furthermore, single-peptide responses were detected in 2 of 12 healthy HLA-A2+ donors, but no responses were detectable in 9 HLA-A2 healthy donors or 4 HLA-A2 melanoma patients. The identified HLA-A*02.01–restricted TRAG-3–derived epitopes are targets for spontaneous immune responses in breast cancer, hematopoietic cancer, and melanoma patients. Hence, these epitopes represent potential target structures for future therapeutic vaccinations against cancer, possibly appropriate for strategies that combine vaccination and chemotherapy; i.e., paclitaxel treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1a–f
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Andersen MH, thor Straten P (2002) Survivin—a universal tumor antigen. Pathol Histopathol 17(2):669–675

    CAS  Google Scholar 

  2. Andersen MH, Tan L, Sondergaard I, Zeuthen J, Elliott T, Haurum JS (2000) Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 55(6):519–531

    Article  CAS  PubMed  Google Scholar 

  3. Andersen MH, Ostergaard Pedersen L, Becker JC, thor Straten P (2001) Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein Survivin in cancer patients. Cancer Res 61:869–872

    CAS  PubMed  Google Scholar 

  4. Anthony DD, Lehmann PV (2003) T-cell epitope mapping using the ELISPOT approach. Methods 29(3):260–269

    Article  CAS  PubMed  Google Scholar 

  5. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196

    CAS  PubMed  Google Scholar 

  6. Bilsborough J, Panichelli C, Duffour MT, Warnier G, Lurquin C, Schultz ES, Thielemans K, Corthals J, Boon T, van Der BP (2002) A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Tissue Antigens 60(1):16–24

    Article  CAS  PubMed  Google Scholar 

  7. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y et al (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63:375–380

    CAS  PubMed  Google Scholar 

  8. Chen W, Masterman KA, Basta S, Mansour Haeryfar SM, Dimopoulos N, Knowles B, Bennink JR, Yewdell JW (2004) Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon. Eur J Immunol 34(1):194–199

    Google Scholar 

  9. Chen Z, Zhu B, Wu Y (2002) Expression of TRAG-3 antigen in non-small-cell lung carcinomas. Lung Cancer 38(1):101–102

    Article  PubMed  Google Scholar 

  10. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Rojas J, Bourdon A, Bonner PL, Wang L, Christmas SE, Travers PJ, Creaser CS, Rees RC, Madrigal JA (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98(10):2887–2893

    Article  CAS  PubMed  Google Scholar 

  11. Coulie PG (2002) Cancer immunotherapy with MAGE antigens. Suppl Tumori 1(4):S63–S65

    PubMed  Google Scholar 

  12. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T (1996) The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 93(14):7149–7153

    Article  PubMed  Google Scholar 

  13. Dionne SO, Smith MH, Marincola FM, Lake DF (2003) Functional characterization of CTL against gp100 altered peptide ligands. Cancer Immunol Immunother 52(4):199–206

    CAS  PubMed  Google Scholar 

  14. Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV (1999) TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229(1–2):75–81

    Article  CAS  PubMed  Google Scholar 

  15. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV (2003) Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9(7):2778–2785

    CAS  PubMed  Google Scholar 

  16. Feller AJ, Duan Z, Penson R, Toh HC, Seiden MV (2000) TRAG-3, a novel cancer/testis antigen, is overexpressed in the majority of melanoma cell lines and malignant melanoma. Anticancer Res 20(6B):4147–4151

    CAS  PubMed  Google Scholar 

  17. Gabrilovich DI (2002) Dendritic cell vaccines for cancer treatment. Curr Opin Mol Ther 4(5):452–458

    CAS  PubMed  Google Scholar 

  18. Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A (2003) Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171(9):4893–4897

    CAS  PubMed  Google Scholar 

  19. Gordan JD, Vonderheide RH (2002) Universal tumor antigens as targets for immunotherapy. Cytotherapy 4(4):317–327

    Article  CAS  PubMed  Google Scholar 

  20. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, Miconnet I, Vonderheide RH, Kosmatopoulos K (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113(3):425–433

    Google Scholar 

  21. Hudis C (2002) Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg. Clin Breast Cancer 3(5):326–332

    CAS  PubMed  Google Scholar 

  22. Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B (2003) Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 4(2):104–109

    Article  CAS  PubMed  Google Scholar 

  23. Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethe B, Connerotte T, Corbiere V, Demoitie MA, Lienard D, Dreno B, Velu T, Boon T, Coulie PG (2003) Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 171(9):4898–4904

    CAS  PubMed  Google Scholar 

  24. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A (2001) Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 167(2):787–796

    CAS  PubMed  Google Scholar 

  25. Kerbel RS (2001) Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer Metastasis Rev 20(1–2):1–2

    Article  CAS  PubMed  Google Scholar 

  26. Khayat D, Antoine EC, Coeffic D (2000) Taxol in the management of cancers of the breast and the ovary. Cancer Invest 18(3):242–260

    CAS  PubMed  Google Scholar 

  27. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Naeyaert JM, Plangne R, Deraemaeker R, Knuth A, Jäger E, Brasseur F, Herman J, Coulie PG, Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883–885

    CAS  PubMed  Google Scholar 

  28. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80(2):219–230

    Article  CAS  PubMed  Google Scholar 

  29. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 (letter). Int J Cancer 63(6):883–885

    CAS  PubMed  Google Scholar 

  30. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328–332

    CAS  PubMed  Google Scholar 

  31. Parmiani G, Rivoltini L, Andreola G, Carrabba M (2000) Cytokines in cancer therapy. Immunol Lett 74(1):41–44

    Article  CAS  PubMed  Google Scholar 

  32. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94(11):805–818

    Google Scholar 

  33. Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA (1998) Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am 4(5):316–323

    CAS  PubMed  Google Scholar 

  34. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL (1996) Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 2(8):1263–1274

    CAS  PubMed  Google Scholar 

  35. Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovi ES (2002) Towards patient-specific tumor antigen selection for vaccination. Immunol Rev 188(1):164–176

    Article  CAS  PubMed  Google Scholar 

  36. Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50(1):3–15

    Article  CAS  PubMed  Google Scholar 

  37. Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC (2003) Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 9(2):657–662

    CAS  PubMed  Google Scholar 

  38. Riley JP, Rosenberg SA, Parkhurst MR (2003) Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities. J Immunol Methods 276(1–2):103–119

    Article  CAS  PubMed  Google Scholar 

  39. Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Levy F, Dutoit V, Ayyoub M, Rubio-Godoy V, Michielin O, Guillaume P, Batard P, Luescher IF, Lejeune F, Lienard D, Rufer N, Dietrich PY, Speiser DE, Cerottini JC (2002) Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 188(1):81–96

    Article  CAS  PubMed  Google Scholar 

  40. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4(3):321–327

    CAS  PubMed  Google Scholar 

  41. Sangrajrang S, Fellous A (2000) Taxol resistance. Chemotherapy 46(5):327–334

    Article  CAS  PubMed  Google Scholar 

  42. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188(1):22–32

    Article  CAS  PubMed  Google Scholar 

  43. Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1

    PubMed  Google Scholar 

  44. Schrama D, Andersen MH, Terheyden P, Schrøder L, Ostergaard Pedersen L, thor Straten P, Becker JC (2001) Oligoclonal TCR usage of melanocyte differentiation antigen-reactive T cells. Cancer Res 61:493–496

    CAS  PubMed  Google Scholar 

  45. Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15(2):138–147

    Article  CAS  PubMed  Google Scholar 

  46. Schultze JL, Vonderheide RH (2001) From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 22(9):516–523

    Article  CAS  PubMed  Google Scholar 

  47. Simon GR, Bunn PA, Jr (2003) Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest 21(1):87–104

    Article  CAS  PubMed  Google Scholar 

  48. Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P (2000) Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60(16):4499–4506

    CAS  PubMed  Google Scholar 

  49. Valmori D, Dutoit V, Rubio-Godoy V, Chambaz C, Lienard D, Guillaume P, Romero P, Cerottini JC, Rimoldi D (2001) Frequent cytolytic T-cell responses to peptide MAGE-A10(254–262) in melanoma. Cancer Res 61(2):509–512

    CAS  PubMed  Google Scholar 

  50. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647

    PubMed  Google Scholar 

  51. van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188(1):51–64

    Article  PubMed  Google Scholar 

  52. Wolff AC (2001) Systemic therapy. Curr Opin Oncol 13(6):436–449

    Article  CAS  PubMed  Google Scholar 

  53. Wu YZ, Zhao TT, Ni B, Zou LY, Liu HL, Zhu B (2003) Expression of TRAG-3 in breast cancer. Int J Cancer 107(1):167–168

    Article  CAS  PubMed  Google Scholar 

  54. Yee C, Greenberg PD (2002) Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2(6):409–419

    Article  CAS  PubMed  Google Scholar 

  55. Zendman AJ, Ruiter DJ, van Muijen GN (2003) Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 194(3):272–288

    Article  CAS  PubMed  Google Scholar 

  56. Zhu B, Chen Z, Cheng X, Lin Z, Guo J, Jia Z, Zou L, Wang Z, Hu Y, Wang D, Wu Y (2003) Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. Clin Cancer Res 9(5):1850–1857

    CAS  PubMed  Google Scholar 

  57. Zinkernagel RM (2002) On cross-priming of MHC class I-specific CTL: rule or exception? Eur J Immunol 32(9):2385–2392

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the EU project “European Searchable Tumour Cell line Database” (ESTDAB), (QLRI-CT-2001-01325), and by grants from The Novo Nordisk Foundation, The Danish Cancer Society, The Danish Research Council, Danish Foundation for Cancer Research, and the Julie von Müllens fund. We thank Professor A. Svejgaard and Ms Bodil K. Jakobsen, Department of Clinical Immunology, University Hospital, Copenhagen, for HLA-typing of patient blood samples.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Per thor Straten.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meier, A., Reker, S., Svane, I.M. et al. Spontaneous T-cell responses against peptides derived from the Taxol resistance–associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunol Immunother 54, 219–228 (2005). https://doi.org/10.1007/s00262-004-0578-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-004-0578-9

Keywords

Navigation